Dr. Frankel is originally from Austin, Texas and received his initial medical training at Harvard University in Boston, Massachusetts.  He completed a research postdoctoral fellowship at the NIH and residency and medical oncology fellowship at Stanford University.  He is board certified in hematology and medical oncology and has a strong clinical background in general medical oncology, and benign and malignant hematology.  His research focus is the preclinical and clinical development of targeted cancer therapeutics.  He leads the Phase 1 Clinical Trials unit at UTSW.  Dr. Frankel’s interests outside of medicine include his family, reading, weight training and walking.


Medical School
Harvard Medical School (1973)
Yale School of Medicine (1974), Internal Medicine
Other Post Graduate Training
National Institutes of Health-Research (1978), Research
Stanford School of Medicine (1980), Internal Medicine
Stanford School of Medicine (1982), Oncology

Clinical Interest


  • Cutaneous Melanoma
  • Eye (Uveal) Melanoma
  • Head & Neck Mucosal Melanoma
  • Metastatic Melanoma
  • Phase I Clinical Trials
  • Primary & Metastatic Gastrointestinal Melanoma
  • Primary & Metastatic Gynecological Melanoma

Research Interest

  • Identification of enrichment biomarkers for response to new cancer drugs
  • Phase 1 clinical trials of novel recombinant protein, nucleic acid and small molecule drugs


Featured Publications LegendFeatured Publications

Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, Neville DM, Woo JH Curr Drug Targets 2009 Feb 10 2 104-9
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE Microb. Pathog. 2008 Jun 44 6 467-72
Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ Blood 1997 Nov 90 9 3654-61
Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC Biochemistry 1996 Nov 35 47 14749-56

Professional Associations/Affiliations

  • American Association for Cancer Research (1989)
  • American Society of Hematology (1989)
  • American Society of Clinical Oncology (1982)